

# ADVANCING DRUG DELIVERY

SATELITE SYMPOSIUM, 13th iMed.ULisboa Meeting



6th July, 2022, 15:00



Faculdade de Farmácia of Universidade de Lisboa

## | Programme

### 15h00 - Opening

João Gonçalves, iMed.ULisboa, Coordinator

### 15h05 – “Drug delivery on the shoulders of giants”

António Almeida, Scientific Board FFUL

### 15h20 - Biopharmaceutics Classification System and beyond

Gordon Amidon, University of Michigan, USA

Marival Bermejo Miguel Hernández University of Elche, ES

### 16h00 - Liposomes in Drug and Vaccine Delivery: A story of Success

Gregory Gregoriadis, London University, UK

Gert Storm, University of Utrecht, NL

### 16h40 - Questions and discussion

### 17h10 - Closing remarks

Beatriz Lima, Dean FFUL

---

### Chair

António Almeida,

Beatriz Lima,

Eugénia Cruz

João Gonçalves

José Moraes



Professor **Gordon L. Amidon** received his B.S. degree from the State University of New York, Buffalo (1967), an M.A. degree in Mathematics (1970) and Ph.D. in Pharmaceutical Chemistry (1971) from The University of Michigan. He was appointed Professor of Pharmaceutics at The University of Michigan in 1983 and was named the Charles R. Walgreen, Jr., Professor of Pharmacy in 1994. Prof. Amidon is internationally known for his research in the field of drug absorption, transport phenomena, solubility and dissolution, and prodrugs. He has published extensively in journals, with over 335 published papers and 370 abstracts, 18 US patents, contributed chapters to over 30 books and monographs and is co-editor of eight books. Professor Amidon has mentored over 80 doctoral and postdoctoral students. He has received numerous awards including; best paper awards in Journal of Pharmaceutical Sciences and Pharmaceutical Research; the Scheele Award of the Swedish Academy of Pharmaceutical Sciences for outstanding contributions to the field of oral drug delivery and biopharmaceutics. He received an honorary Doctor of Pharmacy degree from the University of Uppsala, Sweden; the Founders Award of the Controlled Release Society; the Volwiler Award of the American Association of Colleges of Pharmacy; the AAPS Distinguished Pharmaceutical Scientist Award; the FIP Distinguished Pharmaceutical Scientist Award; the Gerhard Levy Distinguished Lectureship (2006), the Alexander von Humboldt Research Award and the Japan Society for the Promotion of Science (JSPS) Fellowship Award. He has organized and participated in many international symposia and workshops. Dr Amidon developed a Biopharmaceutics Classification System (BCS), with the FDA, impacting bioequivalence standards worldwide. He is a Fellow of the AAPS, APhA/APS, and the AAAS. He served as president of the Controlled Release Society, as well as of AACP, ACS and AAPS. Dr Amidon is the editor of the American Chemical Society Journal, Molecular Pharmaceutics.

---



**Gregory Gregoriadis** is Professor Emeritus, School of Pharmacy, University of London, UK, since 2001. Got a B.Sc. in Chemistry, University of Athens (1957), M.Sc. in Biochemistry (1966) and Ph.D. in Biochemistry by McGill University, Monreal, Canada (1968) and Doctor of Science (DSc), University of London, UK (2001). Worked in many prestigious Institutions such as Max Planck Institut fur Kulturpflanzen-zuchtung, Hamburg; Albert Einstein College of Medicine, New York USA; Royal Free Hospital School of Medicine and at the School of Pharmacy, University of London, UK. Professor Gregoriadis is a scientist of outstanding value recognized worldwide. We owe him the pioneer idea and strategic vision that transformed biomembrane models (liposomes) into drug delivery systems. His early studies identified the crucial characteristics and carried out the experiments in animal models that allowed the utilization of liposomes as the first lipidic nanoparticles as controlled release systems and immunological adjuvants. This concept was applied to treatment of lysosomal storage diseases, cancer, infectious diseases, diabetes, conventional and genetic vaccines. Professor Gregoriadis launched the basis for the production of the first nanodrug based on Liposomes and more recently in the formulation of vaccines against Covid -19. He has published over 350 papers, 250 invited lectures, 18 book chapters, and was Editor of 30 volumes. He invented several clusters of patents, some of which formed the basis of technological platform of Lipoxen Technologies Ltd, a drug delivery company founded and directed by him. He organized and directed 32 Summer Schools and supervised over 100 students of different degrees and nationalities. He was recipient of diverse Awards/Distinctions including Controlled Release Society and Alec D. Bangham MD, FRS Achievement Award, as well of financial support from Institutions as Ministry of Defence, European Commission and of numerous research grants.

